Planttech's carob concentrate has shown remarkable results in improving insulin sensitivity in individuals with elevated glucose levels, according to a recent study conducted by researchers at the University of Murcia (UCAM) and the Biomedical Research Institute of Murcia, Spain. This groundbreaking research, published in the journal Nutrients, not only advances our understanding of carob extract's effects but also highlights its potential in diabetes prevention. The study's findings are particularly exciting, as they demonstrate the extract's ability to positively impact individuals at risk of progressing to Type 2 diabetes mellitus (T2DM).
The key to Planttech's LVLD extract lies in its standardized inositols from carob pods, including D-pinitol, myo-inositol, and D-chiro-inositol. According to Ignacio Zauldua, Planttech CEO, the clinically relevant effects are a result of the synergistic interaction between D-pinitol and the diverse range of naturally occurring carob bioactives within the syrup matrix. This 'entourage effect' includes polyphenols and micronutrient cofactors, creating a powerful combination that supports glucose metabolism and insulin sensitivity.
The study, conducted over 90 days, involved 52 participants, with 25 in the experimental group and 27 in the placebo group. The experimental group received the carob extract, while the placebo group received a placebo. The daily dose was carefully divided into two doses of 3.33 g each, provided in sachets to be diluted in water or juice and consumed 30 minutes before meals. The results were statistically significant, showing improvements in HbA1c, glucose metabolism, and insulin sensitivity in the experimental group.
One of the most intriguing aspects of this study is the mechanism of action behind carob extract's effectiveness. The research notes that an aqueous extract of carob leaves has previously been shown to reduce glucose absorption in both in vivo and in vitro settings. Additionally, a methanolic extract of carob pods demonstrated inhibitory effects against amylase and glucosidase in a streptozotocin-nicotinamide-induced diabetic rat model. These findings suggest that carob-derived products can effectively inhibit key enzymes involved in carbohydrate digestion, contributing to improved glycemic control.
The study's findings have significant implications for diabetes prevention and management. Prediabetes, characterized by elevated blood glucose levels, poses a high risk of progressing to T2DM, a chronic metabolic disorder affecting millions worldwide. The therapeutic potential of medicinal plants, such as carob, is of increasing interest due to their naturally high content of various bioactive compounds, including alkaloids, glycosides, terpenoids, flavonoids, and polyphenols, which exert hypoglycemic activity and antioxidant effects.
Looking ahead, Planttech plans to expand its clinical program with larger and longer-duration studies, focusing on prediabetic and metabolically challenged populations. Zauldua emphasizes the importance of exploring the wider carob bioactive matrix and the 'entourage effect' in supporting glucose regulation and insulin sensitivity. This comprehensive approach to research and development positions Planttech as a leader in the field of natural health solutions, offering exciting possibilities for the future of diabetes prevention and management.
